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BRIEF RESEARCH REPORTSSeveral anticoagulation strategies are used in patients who
receive extracorporeal membrane oxygenation (ECMO).
We report 2 cases in which activated protein C (APC; Xigris;
Eli–Lilly, Indianapolis, Ind) and ECMO were used concom-
itantly for severe refractory acute respiratory distress syn-
drome (ARDS) and septic shock. Both patients had a good
outcome. Heparin-coated ECMO circuits and intravenous
APC without other intravenous anticoagulants might
represent a possible anticoagulation regimen in this patient
population.
CLINICAL SUMMARY
Patient 1
The patient was a 60-year-old man hospitalized because
of community-acquired pneumonia. On admission, he had
severe hypoxemia (partial pressure of oxygen in arterial
blood divided by inspired fraction of oxygen [PaO2/FIO2]
¼ 95) and rapidly required endotracheal intubation, mechan-
ical ventilation, broad-spectrum antibiotics, corticosteroids,
and APC. Twenty-four hours later, he was transferred to
a tertiary care facility to receive continuous renal replace-
ment therapy for acute renal failure and management of sep-
tic shock. His oxygenation deteriorated (PaO2/FIO2 ¼ 85)
despite administration of 100% oxygen and high-frequency
oscillation ventilation. The patient was started on venove-
nous ECMO. The right femoral vein and right internal jug-
ular vein were cannulated percutaneously (28Fr and 19Fr
canulae; Biomedicus; Medtronic, Minneapolis, Minn). The
oxygenator (Quadrox D; Maquet, Hirrlingen, Germany)
and the circuit were heparin coated. APC was used from
the day before initiation of ECMO for 96 hours. After the
end of the APC infusion, intravenous heparin was adminis-
tered on day 3 to achieve a target partial thromboplastin time
of 60 to 100 seconds. No thrombotic or hemorrhagic compli-
cations were observed. ECMO was finally weaned after 2
unsuccessful attempts, and antibiotics were tailored to treat
the Stenotrophomonas maltophilia and Staphylococcus
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secretions. The total ECMO support lasted 5 days. The pa-
tient was weaned from the ventilator 13 days after initiation
of mechanical ventilation and discharged to a peripheral
hospital after 14 days.
Patient 2
In a previously healthy 16-year-old girl who presented
with sore throat and fatigue, a rapid test confirmed the diag-
nosis of mononucleosis. Over the next 48 hours, she experi-
enced severe hypoxic respiratory failure, acute renal failure,
and septic shock. She was treated with endotracheal intuba-
tion, continuous renal replacement therapy, broad-spectrum
antibiotics, corticosteroids, and APC. Despite attempts at
high-frequency oscillation ventilation and inhaled nitric ox-
ide, the PaO2/FIO2 ratio decreased to 42. Emergency venove-
nous ECMO was instituted with a right internal jugular
inflow and a left femoral vein outflow (25Fr and 19Fr canu-
lae, heparin-bonded circuit, and oxygenator). The ECMO
support lasted 5 days. APC was used during the 4 first
days on ECMO, and no anticoagulation was used thereafter.
No thrombotic or hemorrhagic complications were ob-
served. The patient was successfully weaned after 5 days
on ECMO, she was extubated after 11 days, and she returned
home after 20 days. The only positive culture was EBV in
bronchial secretions.
The leukocyte counts, platelet counts, and coagulation
profiles of both patients are displayed in Figure 1. The pres-
sure gradient across the oxygenator and the preoxygenator
pressures are displayed in Figure 2.
DISCUSSION
Severe sepsis complicated by ARDS is associated with
high mortality. Patients with these conditions are treated
aggressively with early, goal-directed therapy1 and might
benefit from the administration of APC2 through its anti-
inflammatory and antithrombotic properties. The use of
APC has been associated with a significant bleeding risk
and has not been reported in patients who are also
receiving ECMO.
ECMO is a last-resort option for life support in patients
who have refractory ARDS. Despite disappointing initial re-
sults,3 ECMO remains a lifesaving option in carefully se-
lected patients. Recent data suggest improved survival in
ECMO-treated patients compared with those receiving con-
ventional treatment.4rgery c July 2009
Brief Research ReportsFIGURE 1. A, Leukocyte count (WBC) from day 0 to day 5 on extracorporeal membrane oxygenation (ECMO). Both patients experienced a decrease in their
leukocyte counts while receiving treatment for sepsis. B, Platelet count (Plt) from day 0 to day 5 on ECMO. Patient 1 had a normal platelet count throughout
the ECMO run. Patient 2 had moderate thrombocytopenia for 2 days during the ECMO run. C, Partial thromboplastin time (PTT) during the ECMO run. After
72 hours on ECMO, heparin infusion was initiated in patient 1. The initial high PTT at initiation of heparin on day 3 in patient 1 might have been caused by an
interaction between APC and heparin. D, International normalized ratio (INR) during the ECMO run. The initial abnormal INR in patient 1 was rapidly cor-
rected during ECMO. Squares, patient 1; diamonds, patient 2.Anticoagulation for ECMO is controversial and is rela-
tively contraindicated in patients at high risk for bleeding.
Anticoagulants that have been used with ECMO include un-
fractionated and low-molecular-weight heparin, argatroban,
and hirudin.5 We report 2 patients with septic shock and
ARDS in which tip-to-tip heparin-coated circuits and APC
FIGURE 2. Preoxygenator pressure and pressure decrease across oxygen-
ator. There were no abnormalities in these pressures for either patient.
ECMO, Extracorporeal membrane oxygenation. Squares, Patient 1; dia-
monds, patient 2.The Journal of Thoracic and Cwere used as principal modalities of anticoagulation. There
were no complications in either case. The other inflamma-
tory and coagulation parameters corrected progressively
while the patients received ECMO and APC, no anemia
was observed, and renal and neurologic function recovered
completely in both cases. No evidence of clotting in the
ECMO circuit was observed. Formal anticoagulation with
intravenous heparin might not be required for ECMO with
heparin-bonded circuits in patients who are already
receiving APC.
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